BMS-663068 Tris

• CAT Number: I005195
• CAS Number: 864953-39-9
• Molecular Formula: C29H37N8O11P
• Molecular Weight: 704.62
• Purity: ≥95%
• Synonyms: 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogenphosphate
• Target: HIV
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 2-amino-2-(hydroxymethyl)propane-1,3-diol;[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
• InChI: InChI=1S/C25H26N7O8P.C4H11NO3/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17;5-4(1-6,2-7)3-8/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38);6-8H,1-3,5H2
• InChIKey: RRGJSMBMTOKHTE-UHFFFAOYSA-N
• SMILES: CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC.C(C(CO)(CO)N)O

BMS-663068 Tris（Cat No.:I005195）is a potent, selective inhibitor of HIV-1 fusion. It targets the viral envelope glycoprotein gp41, preventing the fusion of the virus with host cell membranes and inhibiting viral entry. This compound is developed for the treatment of HIV infections, specifically targeting resistant strains. It shows efficacy in both in vitro and in vivo studies, offering a novel approach to overcoming current antiretroviral therapy limitations. BMS-663068 Tris holds promise as part of combination therapies to improve long-term management of HIV patients.

Reference

[1]. Nowicka-Sans B, Gong YF, McAuliffe B et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507. doi: 10.1128/AAC.00426-12.
[2]. Nettles RE, Schürmann D, Zhu L et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012 Oct 1;206(7):1002-11. doi: 10.1093/infdis/jis432.
[3]. Brown J, Tobyn M, Brown S et al. Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of prodrug. J Int AIDS Soc. 2012 Nov 11;15(6):18266. doi: 10.7448/IAS.15.6.18266.
[4]. Zhou N, Ray N, Healy M et al. Geno- and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in an 8-day monotherapy study of its prodrug BMS-663068. J Int AIDS Soc. 2012 Nov 11;15(6):18270. doi: 10.7448/IAS.15.6.18270.
[5]. Henrich TJ, Kuritzkes DR. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol. 2013 Jan 2. pii: S1879-6257(12)00190-3. doi: 10.1016/j.coviro.2012.12.002.
[6]. Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
[7]. HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections